In particular, the development of inhibitors targeting the constitutive tyrosine kinase activity of FLT3 as a result of mutations targeted to the FLT3 tyrosine kinase domain has been productive for the treatment of FLT3‐mutated AML [115]. Here, FLT3 is linked to acute myeloid leukemia.